Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Recruiting
Observational Study
Lung Cancer Stage III
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 248 (estimated)
- Sponsor
- University Medical Center Groningen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough.
There is a …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* NSCLC, clinical tumor stage III (cT1-4, cN0-3, M0).
* Patient 18 years or older.
* Scheduled for curative intent treatment (surgery and/or radiotherapy).
* Patient able to understand and sign written informed consent.
* Baseline contrast enhanced CT thorax abdomen (or PET/CT),…
Contacts